Basic-alimentary tractAntibodies to CBir1 Flagellin Define a Unique Response That Is Associated Independently With Complicated Crohn’s Disease
Section snippets
Patients
Serum samples from 484 patients (40 normal controls, 21 disease controls, 50 UC patients, and 373 CD patients) were selected from the serum archive of the Cedars-Sinai Inflammatory Bowel Disease Research Center. All research-related activities were approved by the Cedars-Sinai Medical Center institutional review board. The diagnosis for each patient was based on standard endoscopic, histologic, and radiographic features. The normal control group is a collection of environmental controls that
Serum Reactivity to CBir1 Defines a Subset of Patients With CD
Serologic expression cloning of a cecal bacterial antigen phage library identified the flagellin, CBir1, as an immunodominant antigen recognized by colitic mice21 and by approximately half of patients with CD. We used serum from 2 separate cohorts to investigate subgroups of CD patients. Cohort 1 consisted of sera from 100 CD patients selected on the basis of antibody profile. Newly tested sera from a group of 303 unselected patients that were studied and reported on by Mow et al20 comprised
Discussion
Our investigations have yielded compelling evidence that serum antibody to CBir1 flagellin marks for an independent subset of patients with CD. We have shown that the level of response can vary widely, that these responses are relatively stable over time, and these responses do not correspond with active or remission disease states. We know that anti-CBir1 expression is independent of serologic responses to previously defined bacterial antigens and is associated independently with complicated
References (35)
- et al.
Animal models of mucosal inflammation and their relation to human inflammatory bowel disease
Curr Opin Immunol
(1999) - et al.
Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum
Gastroenterology
(1998) - et al.
Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum
Lancet
(1991) - et al.
Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection
Gastroenterology
(1995) - et al.
Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigens
Gastroenterology
(2002) - et al.
Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn’s disease define a clinical subgroup
Gastroenterology
(1996) - et al.
Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease
Gastroenterology
(2004) - et al.
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease
Am J Gastroenterol
(2002) - et al.
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease
Am J Gastroenterol
(2001) - et al.
Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA
J Autoimmun
(2000)
Mast cell and neuroendocrine cytoplasmic autoantigen(s) detected by monoclonal pANCA antibodies
Clin Immunol
The Crohn’s disease-associated bacterial protein I2 is a novel enteric T cell superantigen
Immunity
The immunology of mucosal models of inflammation
Annu Rev Immunol
Mucosal immunity and inflammation. II. The yin and yang of T cells in intestinal inflammation: pathogenic and protective roles in a mouse colitis model
Am J Physiol
CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir miceincreased T helper cell type 1 response and ability to transfer disease
J Exp Med
Colitis induced by enteric bacterial antigen-specific CD4+ T cells requires CD40-CD40 ligand interactions for a sustained increase in mucosal IL-12
J Immunol
Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora
J Immunol
Cited by (410)
Stromal Cell Regulation of Intestinal Inflammatory Fibrosis
2024, Cellular and Molecular Gastroenterology and HepatologyFlagellin-specific human CAR Tregs for immune regulation in IBD
2023, Journal of AutoimmunityAntibody signatures in inflammatory bowel disease: current developments and future applications
2022, Trends in Molecular Medicine
Supported by United States Public Health Service grant PO1DK46763 and a grant from the Edythe and Eli Broad Foundation Medical Research Program.